Thermo Fisher Scientific Myeloperoxidase Recombinant Rabbit Monoclonal Antibody (ZR341)

Applications

Tested Dilution

Publications

Immunohistochemistry (Paraffin) (IHC (P))

1:100-1:200

-

Product Specifications

Host/Isotype

Rabbit / IgG

Class

Recombinant Monoclonal

Type

Antibody

Clone

ZR341

Immunogen

Fragment (around aa 150-250) of human MPO protein if (typeof window.$mangular === undefined || !window.$mangular) { window.$mangular = {}; } $mangular.antigenJson = \[{targetFamily:Myeloperoxidase,uniProtId:P05164-1,ncbiNodeId:9606,antigenRange:150-250,antigenLength:745,antigenImageFileName:Z2647RL_Myeloperoxidase_P05164-1_Rabbit.svg,antigenImageFileNamePDP:Z2647RL_Myeloperoxidase_P05164-1_Rabbit_PDP.jpeg,sortOrder:1}\]; $mangular.isB2BCMGT = false; $mangular.isEpitopesModalImageMultiSizeEnabled = true;

View immunogen .st0{fill:#FFFFFF;} .st1{fill:#1E8AE7;}

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

100 µg/mL

Storage conditions

2-8°C

Shipping conditions

Wet ice

Product Specific Information

A recommended positive control tissue for this product is Bone marrow, however positive controls are not limited to this tissue type.

The primary antibody is intended for laboratory professional use in the detection of the corresponding protein in formalin-fixed, paraffin-embedded tissue stained in manual qualitative immunohistochemistry (IHC) testing. This antibody is intended to be used after the primary diagnosis of tumor has been made by conventional histopathology using non-immunological histochemical stains.

The heme protein myeloperoxidase (MPO) is a major component of azurophilic granules of neutrophils and polymorphonuclear leukocytes. Optimal oxygen-dependent microbiocidal activity depends on MPO as the critical enzyme for the generation of hypochlorous acid and other toxic oxygen products. The MPO precursor is synthesized during the promyelocytic stage of myeloid differentiation and is subsequently processed and transported intracellularly to the lysosomes. The precursor undergoes co-translational N-linked glycosylation to produce a glycoprotein. Glucosidases in the endoplasmic reticulum (ER) or early cis Golgi convert the pro-MPO to a form which is sorted into a pre-lysosomal compartment, which undergoes final proteolytic maturation to native MPO, a pair of heavy-light protomers. In normal neutrophils, MPO is expressed as a dimer. Calreticulin, a calcium-binding protein residing in the ER, interacts specifically with fully glycosylated apo pro-MPO. iMPO mRNA is abundant in human promyelocytic HL-60 and mouse myeloid leukemia NFS-60cells. MPO is expressed at high levels in circulating neutrophils and monocytes but is not detectable in microglia, brain-specific macrophages or normal brain tissue.

Antibody is used with formalin-fixed and paraffin-embedded sections. Pretreatment of deparaffinized tissue with heat-induced epitope retrieval or enzymatic retrieval is recommended. In general, immunohistochemical (IHC) staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody (link antibody), an enzyme complex and a chromogenic substrate with interposed washing steps. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.

A positive tissue control must be run with every staining procedure performed. This tissue may contain both positive and negative staining cells or tissue components and serve as both the positive and negative control tissue. External Positive control materials should be fresh autopsy/biopsy/surgical specimens fixed, processed and embedded as soon as possible in the same manner as the patient sample (s). Positive tissue controls are indicative of correctly prepared tissues and proper staining methods. The tissues used for the external positive control materials should be selected from the patient specimens with well-characterized low levels of the positive target activity that gives weak positive staining. The low level of positivity for external positive controls is designed to ensure detection of subtle changes in the primary antibody sensitivity from instability or problems with the staining methodology. A tissue with weak positive staining is more suitable for optimal quality control and for detecting minor levels of reagent degradation.

Internal or external negative control tissue may be used depending on the guidelines and policies that govern the organization to which the end user belongs to. The variety of cell types present in many tissue sections offers internal negative control sites, but this should be verified by the user. The components that do not stain should demonstrate the absence of specific staining, and provide an indication of non-specific background staining. If specific staining occurs in the negative tissue control sites, results with the patient specimens must be considered invalid.

Target Information

Myeloperoxidase (MPO) is a heme protein that is synthesized during myeloid differentiation and is a major component of neutrophil azurophilic granules. It is produced as a single chain precursor and subsequently cleaved into a light and heavy chain. The mature MPO is a tetramer composed of 2 light chains and 2 heavy chains. This enzyme is responsible for producing hypohalous acids that are central to the microbicidal activity of neutrophils. Diseases that are associated with MPO include Myeloperoxidase Deficiency and Alzheimer`s Disease, Familial, 1.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.